Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Date:10/30/2008

JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that its Chief Executive Officer, Mr. Nadav Kidron, will be giving a company presentation at the 10th Annual Rodman & Renshaw Healthcare Conference at New York City's Palace Hotel on November 11. Mr. Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II Ballroom, located on the 4th floor of the hotel.

"The Rodman & Renshaw Conference will give Oramed an important platform to present the accomplishments we have achieved in our development of an oral insulin capsule and our unique position as a technology pioneer in the field of oral delivery solutions," said Kidron.

For more information about Rodman & Renshaw and the upcoming conference, please visit http://www.rodmanandrenshaw.com/conferences.

For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
6. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
8. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
9. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
10. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
11. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer Experience ... Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and ... of revenues. , Browse 152 market data tables, ... on “Service Quality Management (SQM) and Telco Customer Experience ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... ... Safety Solutions Continues to Accelerate., , ... (PRWEB) June 22, 2010 -- iCardiac Technologies, Inc. , a ... top 20 pharmaceutical companies have recently selected iCardiac as a preferred vendor. iCardiac ...
... 21 A global research team led by scientists ... new study in the Proceedings of the National Academy of ... genome. Lead author, Ewen Kirkness , Ph.D., JCVI, directed ... of the genome was then conducted by a large international ...
... 21 Dyadic International, Inc. (Pink Sheets: DYAI), ... addresses the needs of the multi-billion dollar biofuels market ... biomass into ethanol and other forms of alternative energy, ... firm, The Abraham Group, to provide strategic advice and ...
Cached Biology Technology:Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... of years on tiny islands surrounding Australia have evolved to ... mainland cousins. Now, new research in The American Naturalist ... by the need to have big-mouthed babies. Mainland tiger ... long, patrol swampy areas in search of frogs, their dietary ...
... (OHRI) and the University of Ottawa (uOttawa) have discovered that ... are 35 per cent larger than normal. The research, led ... Developmental Cell , could lead to new approaches to ... disorders such as autism and Rett syndrome. Dr. Picketts ...
... is the most common type of liver disease in the ... NAFLD is often associated with obesity and other parameters ... factor for the development of cardiovascular disease. In a ... that modest alcohol consumption (an average of up to 20 ...
Cached Biology News:Big-mouthed babies drove the evolution of giant island snakes 2Big-mouthed babies drove the evolution of giant island snakes 3Mice with big brains provide insight into brain regeneration and developmental disorders 2
... Immunogen: Fusion protein derived from ... ASIP/PAR-3 (atypical PKC isotype-specific interacting protein/ ... not related to the protease-activated-receptors also ... Xenopus (positive controls: Caco-2 MDCK A6 ...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
...
Request Info...
Biology Products: